scAAV-CMV-GFP (Serotype Retrograde)

scAAV-CMV-GFP (retrograde serotype) is a self-complementary adeno-associated virus (scAAV) vector that exhibits unique characteristics and advantages in the field of molecular biology and gene therapy. The self-complementary nature of scAAV allows for rapid transgene expression, which is particularly beneficial in therapeutic settings requiring immediate gene expression. This vector utilizes a serotype known for its retrograde transport properties, enabling efficient infection of neurons and transport of genetic material back to the neuronal cell body. The inclusion of the CMV (cytomegalovirus) promoter ensures robust and reliable transcription of the inserted GFP (green fluorescent protein) reporter gene, facilitating the monitoring of neuronal activity and health. Furthermore, AAV vectors are known for their low immunogenicity, making them a safer alternative compared to other viral vectors. This characteristic helps minimize immune responses, thereby enhancing the persistence and effectiveness of gene expression in target cells.

This vector is particularly valuable for labeling and tracking neurons in various experimental settings, allowing researchers to study the dynamics of neural circuits and their responses to physiological or pathological stimuli. The use of the GFP reporter gene enables real-time visualization of cellular processes, providing insights into neuronal development, synaptic plasticity, and neurodegeneration. Additionally, scAAV-CMV-GFP can be used in gene therapy applications targeting neurodegenerative diseases such as Alzheimer''s disease, Parkinson''s disease, and spinal muscular atrophy. By delivering therapeutic genes or silencing harmful proteins, this vector may offer new avenues for treatment, potentially slowing or even reversing disease progression. Moreover, the ability to visualize changes in neuronal health and function makes this system a valuable tool for assessing the efficacy of therapeutic interventions.